SIREN L L C
Q3 2026 Form 13-F

GREENWICH, DELAWARE
CIK 0002005245 · Institutional investment manager
Consolidated report · includes 2 managers since Q3 2024
$4.2B Reported Value Total
Reported value
$4.2B
Quarter over quarter
-11.3%
Holdings
110
Top-10 concentration
47.3%

Filing Structure

Reports holdings for

  • Invus Financial Advisors LLC · File #028-19938 · since Q3 2024
  • Invus Group, LLC (not a 13F filer in our records) · File #028-24462 · since Q3 2024

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Raymond Debbane
President

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 12, 2026
Form 13F-HR
Reported value $4.2B
Positions 110
Change in reported value -14.4%
New positions 18
Exited positions 23
Position turnover 30.8%
Top-10 concentration 47.3%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 12, 2026
110 $4.2B
Q2 2026 13F
Filed Aug 13, 2026
115 $4.9B
Q1 2026 13F
Filed May 14, 2026
100 $3.6B
Q4 2025 13F
Filed Feb 13, 2026
113 $3.4B
Q3 2025 13F
Filed Nov 13, 2025
115 $2.6B
Q2 2025 13F
Filed Aug 13, 2025
110 $1.9B
Q1 2025 13F
Filed May 14, 2025
116 $1.8B
Q4 2024 13F
Filed Feb 14, 2025
117 $2.3B
Q3 2024 13F
Filed Nov 13, 2024
109 $2.0B

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 SRRK Scholar Rock Holding Corporation $453.0M 10.71%
2 KYMR Kymera Therapeutics, Inc. $311.3M 7.36%
3 ERAS Erasca, Inc. $193.5M 4.57%
4 RVMD Revolution Medicines, Inc. $174.5M 4.12%
5 ONC BeOne Medicines AG $170.2M 4.02%
6 TNGX Tango Therapeutics, Inc. $169.3M 4.0%
7 MANE Veradermics, Incorporated $160.5M 3.79%
8 ARWR Arrowhead Pharmaceuticals, Inc. $149.9M 3.54%
9 EWTX Edgewise Therapeutics, Inc. $113.8M 2.69%
10 RYTM Rhythm Pharmaceuticals, Inc. $103.4M 2.44%
11 BCAX Bicara Therapeutics Inc $102.4M 2.42%
12 PBLS Parabilis Medicines Inc $96.6M 2.28%
13 LXRX Lexicon Pharmaceuticals, Inc. $83.3M 1.97%
14 SYRE Spyre Therapeutics Inc $77.3M 1.83%
15 TYRA Tyra Biosciences, Inc. $74.3M 1.76%
16 COAG Hemab Therapeutics Holdings Inc $73.0M 1.72%
17 AMLX Amylyx Pharmaceuticals, Inc. $72.2M 1.71%
18 ELVN Enliven Therapeutics, Inc. $67.6M 1.6%
19 SEPN Septerna, Inc. $66.5M 1.57%
20 RCUS Arcus Biosciences, Inc. $62.5M 1.48%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings